Surgery, Multimodal Therapy and Postoperative Quality of Life in Pancreatic Cancer

Dear Colleagues,

Advances in early diagnosis, multimodal treatment and modern follow-up in ductal pancreatic adenocarcinoma (DPAC) are making slow progress when compared, e.g., to colon and rectal cancer or other GI-tumors. New targeted and/or individualized therapies seem to offer some benefit—also to the quality of life of the patients due to lower toxicities. Since about only one third of DPACs can be safely surgically removed (R0-resection), more efforts must be made for early diagnosis, possibly downstaging and resection, and postoperative multimodal treatment with respect to acceptable toxicities. With other malignant tumors of the pancreas, e.g., pancreatic neuroendocrine tumors (P-NETS), prognosis and types of surgery may be different to DPAC. The mode and extent of surgery must be individually chosen using preoperative diagnostic procedures (e.g., PET-CT) and open or minimally invasive—including robotic surgery. Quick postoperative recovery of organ and bodily functions may be improved by the optimal surgical procedure and preoperative physiotherapy. Modern literature gives evidence of the fact that many specialized teams are working on this necessary progress. To reach the goals, a continuous exchange is mandatory, especially in the specialized literature. With experience obtained in one of the top pancreatic surgery centers worldwide, formerly headed by Prof. H. G. Beger, we, the coeditors Karl-H-Link and Michael H. Schoenberg have accumulated ample expertise in this field by specialized pancreatic surgery, multimodal therapies ("ESPAC"), follow-up—also in carcinogenesis and translational research. Publications and many oral presentations worldwide have confirmed that progress in many aspects of patient management in DPAC is facilitated by scientific exchange. Therefore, we do support this Special Issue on Surgery, Multimodal Therapy and Postoperative Quality of Life in Pancreatic Cancer. We would be thrilled if a number of experts accepted our invitation to participate in this scientific exchange by submitting papers concerning the topics addressed.

Prof. Dr. Michael H. Schoenberg
Prof. Dr. Karl Heinrich Link
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-anonymized peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.